Rybak LP, Ramkumar V. Ototoxicity. Kidney Int. 2007;72(8):931–5. https://doi.org/10.1038/sj.ki.5002434.

Søgaard M, Thomsen RW, Bossen KS, Sørensen HT, Nørgaard M. The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013;5(Suppl 1):3–29. https://doi.org/10.2147/CLEP.S47150.

Cheung S, Henderson-Sabes J, Mastick J, et al. Cancer survivors and neurotoxic chemotherapy: hearing loss and tinnitus. BMJ Support Palliat Care. Published online July 27, 2022:bmjspcare-2022–003684. https://doi.org/10.1136/spcare-2022-003684.

Obermair A, Speiser P, Thoma M, et al. Prediction of toxicity but not of clinical course by determining carboplatin exposure in patients with epithelial ovarian cancer treated with a combination of carboplatin and cisplatin. Int J Oncol. 1998;13(5):1023–30. https://doi.org/10.3892/ijo.13.5.1023.

Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother. 2003;4(6):889–901. https://doi.org/10.1517/14656566.4.6.889.

Dreisbach L, Zettner E, Chang Liu M, Meuel Fernhoff C, MacPhee I, Boothroyd A. High-frequency distortion-product otoacoustic emission repeatability in a patient population. Ear Hear. 2018;39(1):85–100. https://doi.org/10.1097/AUD.0000000000000465.

Article  Google Scholar 

Pearson SE, Taylor J, Patel P, Baguley DM. Cancer survivors treated with platinum-based chemotherapy affected by ototoxicity and the impact on quality of life: a narrative synthesis systematic review. Int J Audiol. 2019;58(11):685–95. https://doi.org/10.1080/14992027.2019.1660918.

Article  Google Scholar 

Bielefeld EC, Henderson D. Mechanisms of cisplatin ototoxicity and routes for intervention. Perspect Hear Hear Disord: Res Diagn. 2011;15(1):3–14. https://doi.org/10.1044/hhd15.1.3.

Article  Google Scholar 

Falchook AD, Green R, Knowles ME, et al. Comparison of patient- and practitioner-reported toxic effects associated with chemoradiotherapy for head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2016;142(6):517–23. https://doi.org/10.1001/jamaoto.2016.0656.

Article  Google Scholar 

Ardeshirrouhanifard S, Fossa SD, Huddart R, et al. Ototoxicity after cisplatin-based chemotherapy: factors associated with discrepancies between patient-reported outcomes and audiometric assessments. Ear Hear. 2022;43(3):794–807. https://doi.org/10.1097/AUD.0000000000001172.

Article  Google Scholar 

Miaskowski C, Mastick J, Paul SM, et al. Impact of chemotherapy-induced neurotoxicities on adult cancer survivors’ symptom burden and quality of life. J Cancer Surviv. 2018;12(2):234–45. https://doi.org/10.1007/s11764-017-0662-8.

Article  Google Scholar 

Bass JK, Liu W, Banerjee P, et al. Association of hearing impairment with neurocognition in survivors of childhood cancer. JAMA Oncol. 2020;6(9):1363–71. https://doi.org/10.1001/jamaoncol.2020.2822.

Article  Google Scholar 

US Department of Health and Human Services. (2020). Common Terminology Criteria for Adverse Events. Version 5.0. 2017.

King KA, Brewer CC. Clinical trials, ototoxicity grading scales and the audiologist’s role in therapeutic decision making. Int J Audiol. 2018;57(sup4):S89–98. https://doi.org/10.1080/14992027.2017.1417644.

Article  Google Scholar 

Dillard LK, Lopez-Perez L, Martinez RX, Fullerton AM, Chadha S, McMahon CM. Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: a systematic review and meta-analysis. Cancer Epidemiol. 2022;79:102203. https://doi.org/10.1016/j.canep.2022.102203.

Article  Google Scholar 

Schmidt CM, Knief A, Lagosch AK, Deuster D, am Zehnhoff-Dinnesen A. Left-right asymmetry in hearing loss following cisplatin therapy in children—the left ear is slightly but significantly more affected. Ear Hear. 2008;29(6):830–7. https://doi.org/10.1097/AUD.0b013e31818005a4.

Article  Google Scholar 

Swanepoel DW, Clark JL, Koekemoer D, et al. Telehealth in audiology: the need and potential to reach underserved communities. Int J Audiol. 2010;49(3):195–202. https://doi.org/10.3109/14992020903470783.

Article  Google Scholar 

Wasmann JWA, Lanting CP, Huinck WJ, et al. Computational audiology: new approaches to advance hearing health care in the digital age. Ear Hear. 2021;42(6):1499–507. https://doi.org/10.1097/AUD.0000000000001041.

Article  Google Scholar 

Hastie T, Montanari A, Rosset S, Tibshirani RJ. Surprises in high-dimensional ridgeless least squares interpolation. Ann Stat. 2022;50(2):949–86. https://doi.org/10.1214/21-aos2133.

Article  Google Scholar 

Zuur CL, Simis YJ, Lansdaal PE, et al. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis. Int J Radiat Oncol Biol Phys. 2007;68(5):1320–5. https://doi.org/10.1016/j.ijrobp.2007.01.042.

Article  CAS  Google Scholar 

Frisina RD, Wheeler HE, Fossa SD, et al. Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol. 2016;34(23):2712–20. https://doi.org/10.1200/JCO.2016.66.8822.

Article  CAS  Google Scholar 

Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatr Blood Cancer. 2012;59(1):144–8. https://doi.org/10.1002/pbc.24138.

Article  Google Scholar 

Trendowski MR, El Charif O, Dinh PC Jr, Travis LB, Dolan ME. Genetic and modifiable risk factors contributing to cisplatin-induced toxicities. Clin Cancer Res. 2019;25(4):1147–55. https://doi.org/10.1158/1078-0432.Ccr-18-2244.

Article  CAS  Google Scholar 

Tserga E, Nandwani T, Edvall NK, et al. The genetic vulnerability to cisplatin ototoxicity: a systematic review. Sci Rep. 2019;9(1):3455. https://doi.org/10.1038/s41598-019-40138-z.

Article  CAS  Google Scholar 

Brennan-Jones CG, McMahen C, Van Dalen EC. Cochrane corner: platinum-induced hearing loss after treatment for childhood cancer. Int J Audiol. 2019;58(4):181–4. https://doi.org/10.1080/14992027.2018.1539808.

Article  Google Scholar 

Diepstraten FA, Hoetink AE, van Grotel M, et al. Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review. JAC-Antimicrob Resist. 2021;3(4):dlab184. https://doi.org/10.1093/jacamr/dlab184.

Article  CAS  Google Scholar 

Joo Y, Cruickshanks KJ, Klein BEK, Klein R, Hong O, Wallhagen MI. The contribution of ototoxic medications to hearing loss among older adults. J Gerontol A Biol Sci Med Sci. 2020;75(3):561–6. https://doi.org/10.1093/gerona/glz166.

Article  Google Scholar 

Thein P, Kalinec GM, Park C, Kalinec F. In vitro assessment of antiretroviral drugs demonstrates potential for ototoxicity. Hear Res. 2014;310:27–35. https://doi.org/10.1016/j.heares.2014.01.005.

Article  CAS  Google Scholar 

Dille MF, McMillan GP, Reavis KM, Jacobs P, Fausti SA, Konrad-Martin D. Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model. J Acoust Soc Am. 2010;128(3):1163. https://doi.org/10.1121/1.3473693.

Article  Google Scholar 

Dille MF, Wilmington D, McMillan GP, Helt W, Fausti SA, Konrad-Martin D. Development and validation of a cisplatin dose-ototoxicity model. J Am Acad Audiol. 2012;23(7):510–21. https://doi.org/10.3766/jaaa.23.7.3.

Article  Google Scholar 

Langer T, Clemens E, Broer L, et al. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: results of the European PanCareLIFE cohort study. Eur J Cancer. 2020;138:212–24. https://doi.org/10.1016/j.ejca.2020.07.019.

Article  CAS  Google Scholar 

Pussegoda K, Ross CJ, Visscher H, et al. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther. 2013;94(2):243–51. https://doi.org/10.1038/clpt.2013.80.

Article  CAS  Google Scholar 

Abdollahi H, Mostafaei S, Cheraghi S, Shiri I, Rabi Mahdavi S, Kazemnejad A. Cochlea CT radiomics predicts chemoradiotherapy induced sensorineural hearing loss in head and neck cancer patients: a machine learning and multi-variable modelling study. Phys Med. 2018;45:192–7. https://doi.org/10.1016/j.ejmp.2017.10.008.

Article  Google Scholar 

Deutsch BC, Collopy C, Kallogjeri D, Piccirillo JF. Validation of hearing loss prediction tool for cisplatin chemotherapy and radiation in head and neck cancer treatment. JAMA Otolaryngol Head Neck Surg. 2021;147(2):182–9. https://doi.org/10.1001/jamaoto.2020.4620.

Article  Google Scholar 

Dille MF, Ellingson RM, McMillan GP, Konrad-Martin D. ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring. J Am Acad Audiol. 2013;24(9):769–81. https://doi.org/10.3766/jaaa.24.9.2.

Article  Google Scholar 

Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–65. https://doi.org/10.1200/JCO.2011.34.7625.

Article  CAS  Google Scholar 

American Academy of Audiology. Position statement and clinical practice guidelines: ototoxicity monitoring. n.d. Published online 2009. http://www.audiology.org.

American Speech-Language-Hearing Association. Audiologic management of individuals receiving cochleotoxic drug therapy [Guidelines]. n.d. Published online 1994. Available from www.asha.org/policy.

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097.

Article  Google Scholar 

Wolff RF, Moons KGM, Riley RD, et al. PROBAST: a tool to assess the risk of bias and applicability of prediction model studies. Ann Intern Med. 2019;170(1):51–8. https://doi.org/10.7326/M18-1376.

Article  Google Scholar 

Moons KGM, Wolff RF, Riley RD, et al. PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration. Ann Intern Med. 2019;170(1):W1–33. https://doi.org/10.7326/M18-1377.

Article  Google Scholar 

Theunissen EA, Zuur CL, Jozwiak K, et al. Prediction of hearing loss due to cisplatin chemoradiotherapy. JAMA Otolaryngol Head Neck Surg. 2015;141(9):810–5. https://doi.org/10.1001/jamaoto.2015.1515.

Article  Google Scholar 

Drögemöller BI, Monzon JG, Bhavsar AP, et al. Association between SLC16A5 genetic variation and cisplatin-induced ototoxic effects in adult patients with testicular cancer. JAMA Oncol. 2017;3(11):1558–62. https://doi.org/10.1001/jamaoncol.2017.0502.

Article  Google Scholar 

Schuette A, Lander DP, Kallogjeri D, et al. Predicting hearing loss after radiotherapy and cisplatin chemotherapy in patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2020;146(2):106–12. https://doi.org/10.1001/jamaoto.2019.3550.

Article  Google Scholar 

Wheeler HE, Gamazon ER, Frisina RD, et al. Variants in WFS1 and other mendelian deafness genes are associated with cisplatin-associated ototoxicity. Clin Cancer Res. 2017;23(13):3325–33. https://doi.org/10.1158/1078-0432.CCR-16-2809.

Article  CAS  Google Scholar 

Lee TF, Yeh SA, Chao PJ, et al. Normal tissue complication probability modeling for cochlea constraints to avoid causing tinnitus after head-and-neck intensity-modulated radiation therapy. Radiat Oncol. 2015;10(1):194. https://doi.org/10.1186/s13014-015-0501-x.

Article  CAS  Google Scholar 

Cheraghi S, Nikoofar A, Bakhshandeh M, et al. Normal tissue complication probability modeling of radiation-induced sensorineural hearing loss after head-and-neck radiation therapy. Int J Radiat Biol. 2017;93(12):1327–33. https://doi.org/10.1080/09553002.2017.1385872.

Article  CAS  Google Scholar 

Reavis KM, McMillan G, Austin D, et al. Distortion-product otoacoustic emission test performance for ototoxicity monitoring. Ear Hear. 2011;32(1):61–74. https://doi.org/10.1097/AUD.0b013e3181e8b6a7.

Article  Google Scholar 

Johnson A, Tarima S, Wong S, Friedland DR, Runge CL. Statistical model for prediction of hearing loss in patients receiving cisplatin chemotherapy. JAMA Otolaryngol Head Neck Surg. 2013;139(3):256–64. https://doi.org/10.1001/jamaoto.2013.1713.

Article  Google Scholar 

Fausti SA, Henry JA, Helt WJ, et al. An individualized, sensitive frequency range for early detection of ototoxicity. Ear Hear. 1999;20(6):497–505. https://doi.org/10.1097/00003446-199912000-00005.

Article  CAS